C2N says Samsung’s decision bolsters its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health. Jaywoo Kim, Executive Vice ...
Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial work and R&D pipeline. The conglomerate’s investment—which ...
Hosted on MSN17d
C2N Diagnostics lands $10m cash injection from SamsungC2N Diagnostics has received a $10m strategic investment out of Samsung’s life science investment fund. The US company said the cash injection would help to scale its clinical laboratory ...
C2N Diagnostics LLC said that Samsung C&T Corp., Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corp. all contributed to the $10 million investment. The arm of Samsung focused ...
The investment into C2N Diagnostics shows Samsung’s continued dedication to ... and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results